Biocon Biologics Global PLC, founded in 1978 and based in Bangalore, India, is a biopharmaceutical company dedicated to developing and providing high-quality biosimilars and biologics. The company specializes in a wide range of therapeutic areas, including oncology, diabetes, and autoimmune disorders, positioning itself as a key player in the global biopharmaceutical landscape.
| Bond Name | Country | Maturity | Coupon(%) | |
|---|---|---|---|---|
| BIOLIN 6.67% 2029-10-09 USDBiocon Biologics Global PLC | United Kingdom | 2029-10-09 | 6.670 | 6.22 |
| BIOLIN 6.67% 2029-10-09 USDBiocon Biologics Global PLC | United Kingdom | 2029-10-09 | 6.670 | 6.33 |
Company overview and issue history are AI generated, and should not be cited or relied on without verification.
Biocon Biologics has been active in the bond market since 2021, primarily to finance its growth and expansion initiatives. Notably, in August 2022, the company issued $200 million in green bonds to support its sustainability projects. Currently, the yields on Biocon's bonds are competitive compared to industry averages, offering investors attractive options, particularly in the growing biosimilars segment. Recent news highlights their plans for further issuances to strengthen their balance sheet as they expand into new markets.